Bloodworks Northwest Program for Therapeutic Phlebotomy Patients
In August 2012, Bloodworks Northwest undertook a comprehensive review of its protocol and medical policies for people with conditions treated by blood collection -- known as “therapeutic phlebotomy” (TP). Since that time all people with conditions that are (or may) be treated by TP have been deferred as voluntary blood donors to the community blood supply through the normal collection process, including mobile drives. In the meantime, BloodworksNW’s Therapeutic Phlebotomy Program continued to provide TP treatment at its 11 donor centers for people who require blood withdrawals prescribed by their health care provider.
BloodworksNW’s goal and responsibility is to fulfill its mission as a non-profit but financially sustainable partner in health care with 90 hospitals and treatment centers in the region. To do that in today’s health care environment, BloodworksNW must take into account the resources and expenses associated with drawing patients in its TP program by appropriately billing for these medical services at rates that will recover the costs involved.
Effective July 8, 2013 our TP policies will be updated to reflect compliance with federal regulations, including rigorous verification of a person’s diagnosis and the medical necessity for all TP treatments performed at BloodworksNW centers. BloodworksNW will achieve fair recovery of costs for TP treatments in order to be able to provide this service to the patients in need of it.
Federal regulations and accreditation requirements of the College of American Pathologists require that all TP treatments be supported by a current order from an individual’s health care provider. In providing TP, BloodworksNW must also undertake a diagnostic review for each patient to determine whether the treatment meets the criteria of medical necessity as defined by certification authorities and third party insurance providers, including Medicare. Meeting these responsibilities results in measureable expenditures that reflect the actual costs incurred in providing patients with TP treatment services.
There is strong medical support for TP for people with hereditary hemochromatosis (iron accumulation or overload), non-genetic hemochromatosis, and polycythemia vera (PV) related to marrow overproduction of red cells. Most secondary polycythemia conditions from heart disease, testosterone administration, and others have weaker medical supporting data for the procedure, although the referring physician may order TP in hope of improving the patient’s
In 2003, the Food and Drug Administration (FDA) issued an ‘exception’ policy that allowed TP collections from people diagnosed with HH to be eligible for inclusion in the community blood supply under certain stringent conditions. BloodworksNW gratefully received many donations from community-minded and dedicated HH donors during the period between 2003 and 2012.
Over the past eight months, BloodworksNW thoroughly reviewed its program for obtaining blood from HH donors for use in the community supply. A review of records showed considerable variability in approaches by health care providers – raising concern that HH patients were not consistently distinguished from patients with other, non-genetic causes for iron deposition whose TP collections are not eligible for inclusion in the community supply. We determined that we could no longer use therapeutic donations for the community supply.
BloodworksNW’s goal and responsibility is to fulfill its mission as a non-profit but financially sustainable partner in health care with 70 hospitals and treatment centers in the region. To do that in today’s health care environment, BloodworksNW must take into account the resources and expenses associated with drawing patients in its Therapeutic Phlebotomy program by appropriately billing for these medical services at rates that will recover the costs involved.
In order to recover the costs associated with clinical staff, materials, resources and required medical oversight, charges for TP procedures must in fairness be applied all patients requiring TP.
1. All people needing blood to be drawn as treatment for a diagnosed medical condition must have a valid order from their licensed health care provider -- including those with genetic predisposition to iron overloading (hereditary hemochromatosis, or HH).
2. BloodworksNW has concluded that the medical oversight, complexity, safeguards and risks associated with receiving HH donations into the community blood supply make these collections impractical, and result in costs that are prohibitively high. We do not anticipate that HH donations will be eligible for inclusion in the community blood supply in the foreseeable future.
3. All TP treatments performed by BloodworksNW require that referring physicians complete a Therapeutic Phlebotomy Packet available at psbc.org/therapeuticphlebotomy. This packet includes: an order form based on patient diagnosis, consent form, billing form, Advance Beneficiary Notification (ABN) form, and request for supporting documentation such as lab test results or patient records.
4. BloodworksNW medical staff must receive, review and approve all TP orders and supporting documentation from the TP packet in advance, before treatment commences. All TP orders expire after one year, and must be re-submitted and reviewed by BloodworksNW medical staff.
5. People with TP orders that have been reviewed and approved by BloodworksNW medical staff can receive those treatments by appointment during regular center hours Monday through Friday at any one of BloodworksNW’s 11 donor centers across Western Washington (list attached). TP treatment is not available at mobile blood drives.
6. All TP treatment performed at BloodworksNW centers is subject to cost recovery through the patient’s insurer or from the patient. The cost per TP treatment will be $103.00.
7. Additional safeguards are being implemented to confirm that lab results, condition diagnosis, treatment protocols and medical necessity guidelines meet the established consensus of medical experts. These updated policies and practices are consistent with appropriate medical practice.
We appreciate the understanding of those impacted that these changes are driven by a need to ensure the maximum benefit from community dollars invested in health care, and to fairly recover costs for medical treatments that BloodworksNW provides. The updated policies also reflect diligence to do our utmost to ensure the safety of the community blood supply.
To people with hereditary hemochromatosis: we sincerely appreciate your donations over the past ten years, which benefited countless people in need of blood. We hope any disappointment you feel will not discourage your valued support for BloodworksNW and its commitment to save lives through research, education and excellence in blood, medical and laboratory services in partnership with our community.
To prescribing physicians and patients needing or receiving TP treatment at BloodworksNW centers: we look forward to continuing to serve your needs for therapeutic phlebotomy, and providing you with the highest quality patient care.
Donor Centers Providing Therapeutic Phlebotomy Treatment